Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
Bolt Biotherapeutics (BOLT) - Net Assets
Latest net assets as of September 2025: $32.10 Million USD
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has net assets worth $32.10 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.05 Million) and total liabilities ($32.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.10 Million |
| % of Total Assets | 49.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.83 |
Bolt Biotherapeutics - Net Assets Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bolt Biotherapeutics (2018–2024)
The table below shows the annual net assets of Bolt Biotherapeutics from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $57.20 Million | -49.27% |
| 2023-12-31 | $112.74 Million | -34.26% |
| 2022-12-31 | $171.51 Million | -31.43% |
| 2021-12-31 | $250.12 Million | +338.33% |
| 2020-12-31 | $-104.95 Million | -128.91% |
| 2019-12-31 | $-45.85 Million | -187.56% |
| 2018-12-31 | $-15.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bolt Biotherapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41021900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $97.00K | 0.17% |
| Other Components | $484.50 Million | 847.06% |
| Total Equity | $57.20 Million | 100.00% |
Bolt Biotherapeutics Competitors by Market Cap
The table below lists competitors of Bolt Biotherapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Freightos Limited Warrants
NASDAQ:CRGOW
|
$7.86 Million |
|
Tong Hua Holding Public Company Limited
BK:TH
|
$7.86 Million |
|
Onxeo S.A.
LSE:0NWK
|
$7.86 Million |
|
Tonner Drones S.A.
PA:ALTD
|
$7.86 Million |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
$7.85 Million |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
$7.85 Million |
|
Equites Property Fund Ltd
JSE:EQU
|
$7.85 Million |
|
Nureca Limited
NSE:NURECA
|
$7.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bolt Biotherapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 112,741,000 to 57,198,000, a change of -55,543,000 (-49.3%).
- Net loss of 63,118,000 reduced equity.
- New share issuances of 108,000 increased equity.
- Other comprehensive income increased equity by 60,000.
- Other factors increased equity by 7,407,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.12 Million | -110.35% |
| Share Issuances | $108.00K | +0.19% |
| Other Comprehensive Income | $60.00K | +0.1% |
| Other Changes | $7.41 Million | +12.95% |
| Total Change | $- | -49.27% |
Book Value vs Market Value Analysis
This analysis compares Bolt Biotherapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-8.20 | $4.44 | x |
| 2019-12-31 | $-5.72 | $4.44 | x |
| 2020-12-31 | $-2.90 | $4.44 | x |
| 2021-12-31 | $6.69 | $4.44 | x |
| 2022-12-31 | $4.59 | $4.44 | x |
| 2023-12-31 | $2.98 | $4.44 | x |
| 2024-12-31 | $1.50 | $4.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bolt Biotherapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -110.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -820.78%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.74x
- Recent ROE (-110.35%) is below the historical average (-37.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.99 Million |
| 2019 | 0.00% | -14180.00% | 0.00x | 0.00x | $-25.90 Million |
| 2020 | 0.00% | -26289.18% | 0.00x | 0.00x | $-50.23 Million |
| 2021 | -39.42% | -7824.68% | 0.00x | 1.23x | $-123.60 Million |
| 2022 | -51.37% | -1537.76% | 0.03x | 1.33x | $-105.25 Million |
| 2023 | -61.38% | -878.58% | 0.05x | 1.42x | $-80.47 Million |
| 2024 | -110.35% | -820.78% | 0.08x | 1.74x | $-68.84 Million |
Industry Comparison
This section compares Bolt Biotherapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bolt Biotherapeutics (BOLT) | $32.10 Million | 0.00% | 1.03x | $7.86 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |